Market News & Trends
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
Nkarta Therapeutics recently announced preclinical data highlighting the anti-cancer activity of engineered NK cells in a presentation at the Society of Immunotherapy for Cancer meeting…
Alligator Bioscience & Aptevo Therapeutics Present New Preclinical Data
Alligator Bioscience and Aptevo Therapeutics Inc. recently announced new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting being…
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate
Moleculin Biotech, Inc. recently announced that a new mechanism of action may have been uncovered expanding the potential use of its inhibitor of glycolysis, WP1122.…
Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study
Entera Bio Ltd. recently announced it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with…
Intensity Therapeutics Highlights Data in Advanced Solid Tumors
Intensity Therapeutics, Inc. recently announced additional data from a Phase 1/2 clinical study of INT230-6, the company’s novel lead product candidate designed for direct intratumoral injection,…
Codexis Announces Results of Phase 1a Clinical Trial
Codexis, Inc. recently announced top-line results from its Phase 1a single ascending-dose study in healthy volunteers with CDX-6114, its orally administered enzyme candidate for the…
Enable Injections’ First Closing of Series B Round to Include New Investor
Enable Injections, Inc. recently announced it has completed a first closing of a Series B round that will raise up to $50 million, led by…
Esperion Announces Completion of Phase 3 LDL-C Lowering Development Program
Esperion recently announced completion of the Phase 3 LDL-C Lowering Development Program of bempedoic acid and positive cumulative results. The program consisted of four, pivotal,…
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate From Ionis Pharmaceuticals
ProQR Therapeutics N.V. recently announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly IONIS-RHO-2.5Rx), an RNA medicine for autosomal dominant retinitis…
Athenex Announces FDA Allowance of Investigational New Drug Application
Athenex, Inc. recently announced the FDA has allowed the Investigational New Drug (IND) application for Athenex's oral version of Eribulin currently named Eribulin ORA. This…